FindTrial
Sign In

A prospective randomized controlled study of perioperative application erythropoietin in knee arthroplasty

A prospective randomized controlled study of perioperative application erythropoietin in knee arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063265
Enrollment
Unknown
Registered
2022-09-02
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diseases of knee joints

Interventions

Intervention group 1 :Administer 15,000 units of EPO subcutaneously
Intervention group 2:Administer 30,000 units of EPO subcutaneously

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 55-75 years; 2. Total knee arthroplasty is required for knee diseases; 3. Primary unilateral knee replacement.

Exclusion criteria

Exclusion criteria: 1. EPO use contraindications; 2. the use of iron contraindications; 3. Preoperative anemia, less than 120 g/L in adult males and less than 110 g/L in adult females; 4. Postoperative severe anemia, Hb lower than 60 g/L; 5. Coagulopathy; 6. Hematopoietic dysfunction; 7. Combined with malignant tumors and other systemic diseases; 8. Complicated with kidney diseases; 9. Previous medical history of myocardial infarction, pulmonary infarction, and cerebral infarction.

Design outcomes

Primary

MeasureTime frame
Whole blood cell analysis;thromboelastography;—

Countries

China

Contacts

Public ContactWei Chai

Chinese PLA General Hospital

chaiweiguanjie@sina.com+86 13601372998

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026